tbuckley/cabot-search huggingface dataset:
Luminal-like metastatic breast cancer: which is the room of endocrine maintenance therapy after first line chemotherapy?
Authors: S. Moroso, M. Bonotto, L. Gerratana, G. Arpino, C. De Angelis, D. Iacono, M. Cinausero, M. Milano, P. Gargiulo, C. Fontanella, C. Bozza, V. Fanotto, E. De Carlo, M. Guardascione, S. Russo, C. Andreetta, A.M. Minisini, M. Mansutti, G. Fasola, S. De Placido, F. Puglisi
Journal: Annals of Oncology (2015)
Investigating the effect of tumor vascularization on magnetic targeting in vivo using retrospective design of experiment
Authors: Kuo-Ching Mei, Jie Bai, Silvia Lorrio, Julie Tzu-Wen Wang, Khuloud T. Al-Jamal
Journal: Biomaterials (2016)

Nanocarriers take advantages of the enhanced permeability and retention (EPR) to accumulate passively in solid tumors. Magnetic targeting has shown to further enhance tumor accumulation in response to a magnetic field gradient. It is widely known that passive accumulation of nanocarriers varies hugely in tumor tissues of different tumor vascularization. It is hypothesized that magnetic targeting is likely to be influenced by such factors. In this work, magnetic targeting is assessed in a range of subcutaneously implanted murine tumors, namely, colon (CT26), breast (4T1), lung (Lewis lung carcinoma) cancer and melanoma (B16F10). Passively- and magnetically-driven tumor accumulation of the radiolabeled polymeric magnetic nanocapsules are assessed with gamma counting. The influence of tumor vasculature, namely, the tumor microvessel density, permeability and diameter on passive and magnetic tumor targeting is assessed with the aid of the retrospective design of experiment (DoE) approach. It is clear that the three tumor vascular parameters contribute greatly to both passive and magnetically targeted tumor accumulation but play different roles when nanocarriers are targeted to the tumor with different strategies. It is concluded that tumor permeability is a rate-limiting factor in both targeting modes. Diameter and microvessel density influence passive and magnetic tumor targeting, respectively.
<i>An Old Pond, a Frog Leaps in the Sound of Water</i>
Authors: Carrie A. Butt
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
Authors: Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A. Kate Sasser, Mary E. Guckert, Carla de Boer, Nushmia Z. Khokhar, Howard Yeh, Pamela L. Clemens, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson
Journal: Blood (2016)
Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation
Authors: Christian C. Yost, Hansjörg Schwertz, Mark J. Cody, Jared A. Wallace, Robert A. Campbell, Adriana Vieira-de-Abreu, Claudia V. Araujo, Sebastian Schubert, Estelle S. Harris, Jesse W. Rowley, Matthew T. Rondina, James M. Fulcher, Curry L. Koening, Andrew S. Weyrich, Guy A. Zimmerman
Journal: Journal of Clinical Investigation (2016)

Neutrophil granulocytes, also called polymorphonuclear leukocytes (PMNs), extrude molecular lattices of decondensed chromatin studded with histones, granule enzymes, and antimicrobial peptides that are referred to as neutrophil extracellular traps (NETs). NETs capture and contain bacteria, viruses, and other pathogens. Nevertheless, experimental evidence indicates that NETs also cause inflammatory vascular and tissue damage, suggesting that identifying pathways that inhibit NET formation may have therapeutic implications. Here, we determined that neonatal NET-inhibitory factor (nNIF) is an inhibitor of NET formation in umbilical cord blood. In human neonatal and adult neutrophils, nNIF inhibits key terminal events in NET formation, including peptidyl arginine deiminase 4 (PAD4) activity, neutrophil nuclear histone citrullination, and nuclear decondensation. We also identified additional nNIF-related peptides (NRPs) that inhibit NET formation. nNIFs and NRPs blocked NET formation induced by pathogens, microbial toxins, and pharmacologic agonists in vitro and in mouse models of infection and systemic inflammation, and they improved mortality in murine models of systemic inflammation, which are associated with NET-induced collateral tissue injury. The identification of NRPs as neutrophil modulators that selectively interrupt NET generation at critical steps suggests their potential as therapeutic agents. Furthermore, our results indicate that nNIF may be an important regulator of NET formation in fetal and neonatal inflammation.
Paclitaxel plus BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis: A phase II study.
Authors: A. Tryakin, M. Fedyanin, U. Sergeev, I. Pokataev, B. Ahmedov, T. Zakharova, A. Mitin, I. Fainstein, A. Garin, S. Tjulandin
Journal: Journal of Clinical Oncology (2010)

4587 Background: Paclitaxel is an active drug in the treatment of patients (pts) with NSGCT. We performed a phase II study to assess the efficacy and toxicity of T-BEP regimen in the first line treatment of NSGCT pts with poor prognosis. Methods: CT-naïve NSGCT pts with poor prognosis (IGCCCG) received T-BEP as follows: paclitaxel 175 mg/m2 d 2, cisplatin 20 mg/m2 d 1-5, etoposide 100 mg/m2 d1-5, bleomycin 30 IU d 1,3,5 with G-CSF support 300 mcg d 6-15. Four–six cycles of CT were administered depending on time to normalization of tumor markers. The primary endpoint was the progression free rate at 1-year after completion of CT. The hypotheses being tested was Ho: p0 = pexp (p0=0.50). Assuming pexp=0.70 with a two-sided type I error of 0.05, a type II error of 0.2 and 10% of pts drop-out rate, 51 pts were required. Results: From 2004 to 2008, 51 pts were treated. Sixteen (30%) pts had primary mediastinal tumor. Median follow-up (f.-up) of survived pts was 26 months (range, 6 – 54). Complete response (CR) after CT and surgery was achieved in 11 (22%) pts. Twenty eight (55%) pts had partial response (PR) marker “-“ status, 3 (6%) pts – PR marker “+”, and 9 (17%) pts were classified as treatment failure (progression disease or incomplete resection of viable tumor). When 27 pts had been treated, an unplanned analysis showed inappropriate toxicity on cycle 1 (6 pts had infection gr. 3/4, which resulted in two toxic deaths). Thereafter, the regimen was modified: the next 26 pts started BEP regimen on cycle 1 followed by T-BEP on subsequent cycles. No more severe infections or toxic deaths were observed in the cohort. For all pts, toxicity (grade 3/4) included neutropenia 70%, febrile neutropenia 34%, mucositis 4% and diarrhea 2%. A patient was lost for follow-up (follow-up <1 year) and efficacy was assessed in 50 pts. At 1-year after completion of CT 26 (58%) pts were free of disease, which was compatible with results of BEP alone. Conclusions: T-BEP regimen does not improve outcome of NSGCT pts with poor prognosis. No significant financial relationships to disclose.
Plan de préparation et réponse à la pandémie de grippe au niveau de la Communauté européenne
Authors: Franz Karcher, Hartmut Buchow
Journal: Eurosurveillance (2002)

En novembre 2001, la Commission europeenne a invite des experts de toute l’Europe a exprimer leurs points de vue sur les differentes facons d’ameliorer la preparation a une pandemie de grippe au niveau europeen. La conference a ete bien suiv
P0505 : Identification of IL-17 positive intrahepatic NK cells in human liver and relationship with chronic liver diseases
Authors: Z. Macek Jilkova, H. Marche, C. Gierczak, V. Leroy, J.-P. Zarski, T. Decaens, P.N. Marche, N. Sturm, E. Jouvin-Marche
Journal: Journal of Hepatology (2015)
Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure
Authors: Stephanus T Malherbe, Shubhada Shenai, Katharina Ronacher, Andre G Loxton, Gregory Dolganov, Magdalena Kriel, Tran Van, Ray Y Chen, James Warwick, Laura E Via, Taeksun Song, Myungsun Lee, Gary Schoolnik, Gerard Tromp, David Alland, Clifton E Barry, Jill Winter, Gerhard Walzl, Lance Lucas, Gian van der Spuy, Kim Stanley, Lani Thiart, Bronwyn Smith, Nelita Du Plessis, Caroline G G Beltran, Elizna Maasdorp, Annare Ellmann, Hongjo Choi, Joonsung Joh, Lori E Dodd, Brian Allwood, Coenie Koegelenberg, Morné Vorster, Stephanie Griffith-Richards
Journal: Nature Medicine (2016)
A Phase III Study of New Synthetic Retinoid Tamibarotene(Am80) Compared with ATRA in Maintenance Therapy for Newly Diagnosed Acute Promyelocytic Leukemia (APL): Japan Adult Leukemia Study Group (JALSG) APL204 Study
Authors: Katsuji Shinagawa, Shigeki Ohtake, Toru Sakura, Yasunori Ueda, Masashi Sawa, Jun-ichi Miyatake, Noriko Usui, Makoto Onitsuka, Yoshihiro Hatta, Nobuhiko Emi, Shigehisa Tamaki, Yoshikazu Ito, Toru Murayama, Hiroyuki Fujita, Katsumichi Fujimaki, Norio Asou, Akihiro Takeshita, Yasushi Miyazaki, Shuichi Miyawaki, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno
Journal: Blood (2012)
Body Fatness and Cancer — Viewpoint of the IARC Working Group
Authors: Béatrice Lauby-Secretan, Chiara Scoccianti, Dana Loomis, Yann Grosse, Franca Bianchini, Kurt Straif
Journal: New England Journal of Medicine (2016)

The International Agency for Research on Cancer convened a workshop on the relationship between body fatness and cancer, from which an IARC handbook on the topic will appear. An executive summary of the evidence is presented.
Cautionary Note on Using Cross-Validation for Molecular Classification
Authors: Li-Xuan Qin, Huei-Chung Huang, Colin B. Begg
Journal: Journal of Clinical Oncology (2016)

Purpose Reproducibility of scientific experimentation has become a major concern because of the perception that many published biomedical studies cannot be replicated. In this article, we draw attention to the connection between inflated overoptimistic findings and the use of cross-validation for error estimation in molecular classification studies. We show that, in the absence of careful design to prevent artifacts caused by systematic differences in the processing of specimens, established tools such as cross-validation can lead to a spurious estimate of the error rate in the overoptimistic direction, regardless of the use of data normalization as an effort to remove these artifacts. Methods We demonstrated this important yet overlooked complication of cross-validation using a unique pair of data sets on the same set of tumor samples. One data set was collected with uniform handling to prevent handling effects; the other was collected without uniform handling and exhibited handling effects. The paired data sets were used to estimate the biologic effects of the samples and the handling effects of the arrays in the latter data set, which were then used to simulate data using virtual rehybridization following various array-to-sample assignment schemes. Results Our study showed that (1) cross-validation tended to underestimate the error rate when the data possessed confounding handling effects; (2) depending on the relative amount of handling effects, normalization may further worsen the underestimation of the error rate; and (3) balanced assignment of arrays to comparison groups allowed cross-validation to provide an unbiased error estimate. Conclusion Our study demonstrates the benefits of balanced array assignment for reproducible molecular classification and calls for caution on the routine use of data normalization and cross-validation in such analysis.
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Authors: Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz, Matthias Simon, Boris Krischek, E Zeynep Erson-Omay, Octavian Henegariu, Geneive Carrión-Grant, Ketu Mishra-Gorur, Daniel Durán, Johanna E Goldmann, Johannes Schramm, Roland Goldbrunner, Joseph M Piepmeier, Alexander O Vortmeyer, Jennifer Moliterno Günel, Kaya Bilgüvar, Katsuhito Yasuno, Richard A Young, Murat Günel
Journal: Nature Genetics (2016)
An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation
Authors: Eilis Hannon, Emma Dempster, Joana Viana, Joe Burrage, Adam R. Smith, Ruby Macdonald, David St Clair, Colette Mustard, Gerome Breen, Sebastian Therman, Jaakko Kaprio, Timothea Toulopoulou, Hilleke E. Hulshoff Pol, Marc M. Bohlken, Rene S. Kahn, Igor Nenadic, Christina M. Hultman, Robin M. Murray, David A. Collier, Nick Bass, Hugh Gurling, Andrew McQuillin, Leonard Schalkwyk, Jonathan Mill
Journal: Genome biology (2016)

Schizophrenia is a highly heritable, neuropsychiatric disorder characterized by episodic psychosis and altered cognitive function. Despite success in identifying genetic variants associated with schizophrenia, there remains uncertainty about the causal genes involved in disease pathogenesis and how their function is regulated.We performed a multi-stage epigenome-wide association study, quantifying genome-wide patterns of DNA methylation in a total of 1714 individuals from three independent sample cohorts. We have identified multiple differentially methylated positions and regions consistently associated with schizophrenia across the three cohorts; these effects are independent of important confounders such as smoking. We also show that epigenetic variation at multiple loci across the genome contributes to the polygenic nature of schizophrenia. Finally, we show how DNA methylation quantitative trait loci in combination with Bayesian co-localization analyses can be used to annotate extended genomic regions nominated by studies of schizophrenia, and to identify potential regulatory variation causally involved in disease.This study represents the first systematic integrated analysis of genetic and epigenetic variation in schizophrenia, introducing a methodological approach that can be used to inform epigenome-wide association study analyses of other complex traits and diseases. We demonstrate the utility of using a polygenic risk score to identify molecular variation associated with etiological variation, and of using DNA methylation quantitative trait loci to refine the functional and regulatory variation associated with schizophrenia risk variants. Finally, we present strong evidence for the co-localization of genetic associations for schizophrenia and differential DNA methylation.
Lenalidomide Promotes a Pro-Inflammatory Switch of Nurse-like Cells Derived from Chronic Lymphocytic Leukemia
Authors: Rossana Maffei, Stefania Fiorcari, Silvia Martinelli, Jenny Bulgarelli, Valentina Audrito, Patrizia Zucchini, Giulia Debbia, Elisabetta Colaci, Leonardo Potenza, Franco Narni, Silvia Deaglio, Mario Luppi, Roberto Marasca
Journal: Blood (2014)
A Multicomponent Animal Virus Isolated from Mosquitoes
Authors: Jason T. Ladner, Michael R. Wiley, Brett Beitzel, Albert J. Auguste, Alan P. Dupuis, Michael E. Lindquist, Samuel D. Sibley, Krishna P. Kota, David Fetterer, Gillian Eastwood, David Kimmel, Karla Prieto, Hilda Guzman, Matthew T. Aliota, Daniel Reyes, Ernst E. Brueggemann, Lena St. John, David Hyeroba, Michael Lauck, Thomas C. Friedrich, David H. O’Connor, Marie C. Gestole, Lisa H. Cazares, Vsevolod L. Popov, Fanny Castro-Llanos, Tadeusz J. Kochel, Tara Kenny, Bailey White, Michael D. Ward, Jose R. Loaiza, Tony L. Goldberg, Scott C. Weaver, Laura D. Kramer, Robert B. Tesh, Gustavo Palacios
Journal: Cell Host & Microbe (2016)
Pax5 Activates Oncogenic Transcription Factors of the Ets Family by Repressing the mir-15a/16-1 microRNA Cluster.
Authors: Elaine Y. Chung, Diana Cozma, Duonan Yu, Michael Dews, Erik A. Wentzel, Tsung-Cheng Chang, Joshua T. Mendell, Andrei Thomas-Tikhonenko
Journal: Blood (2007)
Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer.
Authors: Gun Min Kim, Joong Bae Ahn, Jung Woo Han, Han Sang Kim, Sang Joon Shin, Woo Sun Kwon, Chan Hee Park, Tae Soo Kim, Sungwhan An, Im-Hee Shin, Woo Ick Yang, Nam Kyu Kim, Hyun Cheol Chung
Journal: Journal of Clinical Oncology (2012)

3606 Background: Mucinous adenocarcinoma (MC) is a histological subtype of colorectal cancer with ≥50% of mucinous component of tumor volume. According to WHO classification, tumor less than 50% of the lesion composed of mucin was considered as non-mucinous carcinoma (NMC).Mucinous histology has been shown to be an independent adverse prognostic factor in some studies, but not in others. However, prognostic implication of intermediate mucinous carcinoma (IMC) which had focal mucinous component &lt;50% of tumor volume has not been studied yet. The aim of this study is to explore prognostic impact of IMC in patients with resected stage II or III colon cancer. Methods: This study involved 917 patients who underwent curative resection for stage II or III colon cancer in Severance Hospital, from 2003 to 2009. The proportion of mucinous component was reviewed and re-classified correctly by pathologists. MC was defined tumor having &gt;50% mucinous component. Tumor with mucinous component but less than 50% regarded as IMC and less than 10% mucin as NMC. Results: Among 917 patients, 63 (6.9%) and 60 (6.5%) were MC and IMC, respectively. Median follow-up duration was 50.2 months (0.9~109.7) and Stage 3 was 48.1% (441/917). The similarities between MC and IMC were found as right colon dominant (MC: IMC: NMC = 60%: 67%: 34%, p&lt;.001) and higher incidence of MSI-high compared to NMC (MC: IMC: NMC = 27%: 30%: 11%, p&lt;.001). In stage III, the disease-free survival (DFS) rate at 5 years was 44% for MC, 56% for IMC, and 74% for NMC (p&lt;.001). Subgroup analysis according to MSI status showed that DFS had significant inverse correlation with proportions of mucinous components in MSI-low or MSS group, but patients with MSI-high tumor showed higher five-year DFS rate (&gt;85%) regardless of mucinous component. For stage II colon cancer patients, both mucinous histology and MSI had little clinical significance. Conclusions: In patients with curative resection for stage II or III colon cancer, IMC had similar characteristics to MC, which were right colon dominant and high incidence of MSI-high tumor. The prognostic impact of IMC was intermediate risk between MC and NMC in stage III patients with MSI-low or MSS tumor, but not in MSI-high group.
Endoscopic anti-reflux valve for post-esophagectomy reflux: an animal study
Authors: Yoshitomo Yanagimoto, Makoto Yamasaki, Hirotsugu Nagase, Takashi Kanemura, Shigeyoshi Higashi, Yasuhiro Miyazaki, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Hiroshi Miyata, Shuji Takiguchi, Masaki Mori, Yuichiro Doki, Kiyokazu Nakajima
Journal: Endoscopy (2016)

<b>Background and study aims: </b>Gastric reflux into the remnant esophagus after subtotal or partial esophagectomy is associated with impairment in patient quality of life. We evaluated the feasibility, safety, and potential effectiveness of a novel procedure using a new endoscopic suturing device to create an anti-reflux valve (funnel) in pigs after esophagectomy with gastric tube reconstruction. <b>Methods: </b>The endoscopic procedure was performed in four pigs using a semi-full-thickness endoscopic suturing system (OverStitch; Apollo Endosurgery, Austin, Texas, USA). The operating time, funnel height, ratio of the height of the funnel to the diameter of the gastric tube, and adverse events associated with the procedure were evaluated. The "reflux angle" was measured morphologically and functionally during a reflux induction test, using contrast medium or artificial gastric fluid, by tilting the operating table gradually from a head up to a head down position. Reflux angles before and after funnel creation were compared. <b>Results: </b>The procedure was successful in all four animals. The median operating time was 43 minutes, and the median funnel height was 17 mm (56.7 % of gastric tube diameter). There were no adverse events associated with the procedure. The reflux angle was lower after the procedure compared with before in both morphological and functional assessments in all four cases. <b>Conclusions: </b>Endoscopic anti-reflux funnel creation using OverStitch was feasible, safe, and potentially effective.
Response: Table 1.
Authors: Amanda B. Spurdle, Susan Domchek, Mark Robson, Saundra Buys, Paolo Radice, Miguel de la Hoya, Peter Devilee, Alvaro N. A. Monteiro, Melissa Southey, Diana Eccles, Fergus J. Couch, David E. Goldgar
Journal: JNCI Journal of the National Cancer Institute (2016)
Authors’ reply to Timms and Bird
Authors: Minna Johansson, Karsten Juhl Jørgensen, Linn Getz, Ray Moynihan
Journal: BMJ (2016)

We endorse Timms and Bird’s preference for lifestyle adjustments as the first issues to discuss over “active treatment.”1 2 However, GPs often don’t have enough time, making it attractive to resort to medicalisation. Few patients succeed in lowering blood pressure or blood lipids below recommended values through lifestyle changes, at least in the longer term.

We’re glad that Dr Timms has not experienced stigmatisation …